@article{perveen_randomized_2022,
	title = {A {Randomized} {Trial} of {Oral} {Tranexamic} {Acid} {With} {Fluocinolone}-{Based} {Triple} {Cream} {Versus} {Fluocinolone} {Based} {Triple} {Cream} {Alone} for the {Treatment} of {Melasma}},
	volume = {21},
	copyright = {All rights reserved},
	issn = {1545-9616 (Print) 1545-9616},
	doi = {10.36849/jdd.6099},
	abstract = {Oral tranexamic acid (TXA) is a relatively new treatment option for melasma. It is thought to reduce hyperpigmentation through inhibition of the plasminogen/plasmin pathway with resulting decreases in epidermal melanocyte tyrosinase activity, inflammatory mediators, dermal neovascularization, and mast cell numbers.},
	language = {eng},
	number = {3},
	journal = {J Drugs Dermatol},
	author = {Perveen, S. and Rubin, A. and Berger, L. and Xiong, W. and Waqas, N. and Sharif, S. and Rao, B.},
	month = mar,
	year = {2022},
	keywords = {*Hyperpigmentation, *Melanosis/diagnosis/drug therapy, *Tranexamic Acid, Fluocinolone Acetonide/analogs \& derivatives, Humans, Treatment Outcome},
	pages = {321--322},
}

{"_id":"RAucXCEGWsjNNYHQQ","bibbaseid":"perveen-rubin-berger-xiong-waqas-sharif-rao-arandomizedtrialoforaltranexamicacidwithfluocinolonebasedtriplecreamversusfluocinolonebasedtriplecreamaloneforthetreatmentofmelasma-2022","author_short":["Perveen, S.","Rubin, A.","Berger, L.","Xiong, W.","Waqas, N.","Sharif, S.","Rao, B."],"bibdata":{"bibtype":"article","type":"article","title":"A Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma","volume":"21","copyright":"All rights reserved","issn":"1545-9616 (Print) 1545-9616","doi":"10.36849/jdd.6099","abstract":"Oral tranexamic acid (TXA) is a relatively new treatment option for melasma. It is thought to reduce hyperpigmentation through inhibition of the plasminogen/plasmin pathway with resulting decreases in epidermal melanocyte tyrosinase activity, inflammatory mediators, dermal neovascularization, and mast cell numbers.","language":"eng","number":"3","journal":"J Drugs Dermatol","author":[{"propositions":[],"lastnames":["Perveen"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Rubin"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Berger"],"firstnames":["L."],"suffixes":[]},{"propositions":[],"lastnames":["Xiong"],"firstnames":["W."],"suffixes":[]},{"propositions":[],"lastnames":["Waqas"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Sharif"],"firstnames":["S."],"suffixes":[]},{"propositions":[],"lastnames":["Rao"],"firstnames":["B."],"suffixes":[]}],"month":"March","year":"2022","keywords":"*Hyperpigmentation, *Melanosis/diagnosis/drug therapy, *Tranexamic Acid, Fluocinolone Acetonide/analogs & derivatives, Humans, Treatment Outcome","pages":"321–322","bibtex":"@article{perveen_randomized_2022,\n\ttitle = {A {Randomized} {Trial} of {Oral} {Tranexamic} {Acid} {With} {Fluocinolone}-{Based} {Triple} {Cream} {Versus} {Fluocinolone} {Based} {Triple} {Cream} {Alone} for the {Treatment} of {Melasma}},\n\tvolume = {21},\n\tcopyright = {All rights reserved},\n\tissn = {1545-9616 (Print) 1545-9616},\n\tdoi = {10.36849/jdd.6099},\n\tabstract = {Oral tranexamic acid (TXA) is a relatively new treatment option for melasma. It is thought to reduce hyperpigmentation through inhibition of the plasminogen/plasmin pathway with resulting decreases in epidermal melanocyte tyrosinase activity, inflammatory mediators, dermal neovascularization, and mast cell numbers.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {J Drugs Dermatol},\n\tauthor = {Perveen, S. and Rubin, A. and Berger, L. and Xiong, W. and Waqas, N. and Sharif, S. and Rao, B.},\n\tmonth = mar,\n\tyear = {2022},\n\tkeywords = {*Hyperpigmentation, *Melanosis/diagnosis/drug therapy, *Tranexamic Acid, Fluocinolone Acetonide/analogs \\& derivatives, Humans, Treatment Outcome},\n\tpages = {321--322},\n}\n\n\n\n","author_short":["Perveen, S.","Rubin, A.","Berger, L.","Xiong, W.","Waqas, N.","Sharif, S.","Rao, B."],"key":"perveen_randomized_2022","id":"perveen_randomized_2022","bibbaseid":"perveen-rubin-berger-xiong-waqas-sharif-rao-arandomizedtrialoforaltranexamicacidwithfluocinolonebasedtriplecreamversusfluocinolonebasedtriplecreamaloneforthetreatmentofmelasma-2022","role":"author","urls":{},"keyword":["*Hyperpigmentation","*Melanosis/diagnosis/drug therapy","*Tranexamic Acid","Fluocinolone Acetonide/analogs & derivatives","Humans","Treatment Outcome"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/raoresearch","dataSources":["5i38dLwPk6C3jurSL","aGgndugSyribdb2rd","2tgmyzKov4y6MHvQs"],"keywords":["*hyperpigmentation","*melanosis/diagnosis/drug therapy","*tranexamic acid","fluocinolone acetonide/analogs & derivatives","humans","treatment outcome"],"search_terms":["randomized","trial","oral","tranexamic","acid","fluocinolone","based","triple","cream","versus","fluocinolone","based","triple","cream","alone","treatment","melasma","perveen","rubin","berger","xiong","waqas","sharif","rao"],"title":"A Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma","year":2022}